Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06167707 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers
A Phase 1 study, sponsored by scPharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT06167707: Completed Phase 1 study, sponsored by scPharmaceuticals.
NCT06167707 is a Phase 1 study that has completed, run by scPharmaceuticals. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06167707, a Phase 1 study, has completed, sponsored by scPharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study aims to compare the pharmacokinetics and pharmacodynamics of subcutaneous (SC) and intravenous (IV) furosemide. The test formulation in this study is furosemide injection, 80 mg/1 mL, buffered to a neutral pH for SC administration via an autoinjector. A commercial formulation of furosemide injection, USP, solution 10 mg/mL administered as a 40 mg IV injection over 2 minutes followed by a second dose of 40 mg, 2 hours later, will serve as the reference drug. The objectives of this study are: * To estimate the bioavailability and describe the pharmacokinetics and pharmacodynamics of furosemide administered as SC injection via autoinjector compared with equivalent dose of furosemide administered as two 40 mg IV injections, two hours apart. * To describe the safety and tolerability of furosemide administered as SC injection via an autoinjector.
Interventions
- DRUG SCP-111
- DRUG Furosemide USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2024-04-19 |
| Est. Completion | 2024-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06167707
The ClinicalTrials.gov registry entry for NCT06167707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is scPharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SCP-111 is the first listed.
NCT06167707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06167707 about?
NCT06167707 is a clinical study titled "Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers". This study aims to compare the pharmacokinetics and pharmacodynamics of subcutaneous (SC) and intravenous (IV) furosemide. The test formulation in this study is furosemide injection, 80 mg/1 mL, buffered to a neutral pH for SC administration via an autoinjector. A commercial formulation of furosemid...
What is the current status of trial NCT06167707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2024-04-19. Estimated completion is 2024-06-14.
What interventions are being tested in trial NCT06167707?
The interventions under investigation include: SCP-111 (DRUG), Furosemide USP (DRUG).
Who is sponsoring clinical trial NCT06167707?
This trial is sponsored by scPharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.